{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:23:41Z","timestamp":1789093421853,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jns.2021.120009","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T15:03:53Z","timestamp":1632755033000},"page":"120009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The association between developing Parkinson's disease and \u03b2-Adrenoceptor acting agents use: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"430","author":[{"given":"Weerawat","family":"Saengphatrachai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulsatree","family":"Praditukrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvadee","family":"Pitakpatapee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachaya","family":"Srivanitchapoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jns.2021.120009_bb0005","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"issue":"16 Pt 2","key":"10.1016\/j.jns.2021.120009_bb0010","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2021.120009_bb0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.52.6.1214","article-title":"Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990","volume":"52","author":"Bower","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2021.120009_bb0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.2042-7158.1984.tb06941.x","article-title":"Kinetics and distribution of the beta-adrenergic agonist salbutamol in rat brain","volume":"36","author":"Caccia","year":"1984","journal-title":"J. Pharm. Pharmacol."},{"issue":"5","key":"10.1016\/j.jns.2021.120009_bb0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/phar.2383","article-title":"Effects of \u03b22-adrenergic agonists on risk of Parkinson\u2019s disease in COPD: a population-based study","volume":"40","author":"Chen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.jns.2021.120009_bb0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40263-020-00736-2","article-title":"\u03b2-Adrenoceptor drugs and Parkinson\u2019s disease: a nationwide nested case-control study","volume":"34","author":"de Germay","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2021.120009_bb0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.biochi.2020.12.002","article-title":"Levalbuterol lowers the feedback inhibition by dopamine and delays misfolding and aggregation in tyrosine hydroxylase","volume":"183","author":"Flydal","year":"2021","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.jns.2021.120009_bb0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/aje\/kwaa012","article-title":"\u03b2 2-agonists and the incidence of Parkinson disease","volume":"189","author":"Giorgianni","year":"2020","journal-title":"Am. J. Epidemiol."},{"issue":"9","key":"10.1016\/j.jns.2021.120009_bb0045","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jns.2021.120009_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.parkreldis.2004.02.010","article-title":"DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia","volume":"10","author":"H\u00e5kansson","year":"2004","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.jns.2021.120009_bb0055","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1471-4159.2010.06668.x","article-title":"Role of adrenoceptors in the regulation of dopamine\/DARPP-32 signaling in neostriatal neurons","volume":"113","author":"Hara","year":"2010","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.jns.2021.120009_bb0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.jns.2021.120009_bb0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2021.120009_bb0070","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/WNL.0000000000007694","article-title":"Use of \u03b22-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease","volume":"93","author":"Hopfner","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2021.120009_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(19)30400-4","article-title":"\u03b2-Adrenoreceptors and the risk of Parkinson\u2019s disease","volume":"19","author":"Hopfner","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120009_bb0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbi.2016.07.162","article-title":"\u03b2-Adrenergic-stimulated macrophages: comprehensive localization in the M1-M2 spectrum","volume":"57","author":"Lamkin","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.jns.2021.120009_bb0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1533317513488919","article-title":"The role of \u03b2-adrenergic blockers in Parkinson\u2019s disease: possible genetic and cell-signaling mechanisms","volume":"28","author":"Luong","year":"2013","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"issue":"2","key":"10.1016\/j.jns.2021.120009_bb0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0163-7258(90)90092-G","article-title":"Beta-blockers and central nervous system side effects","volume":"46","author":"McAinsh","year":"1990","journal-title":"Pharmacol. Ther."},{"issue":"6354","key":"10.1016\/j.jns.2021.120009_bb0095","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jns.2021.120009_bb0100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/aje\/kwr081","article-title":"Prediction model of Parkinson\u2019s disease based on antiparkinsonian drug claims","volume":"174","author":"Moisan","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.jns.2021.120009_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000054770","article-title":"Risk factors for parkinson\u2019s disease: the leisure world cohort study","volume":"20","author":"Paganini-Hill","year":"2001","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2021.120009_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lfs.2019.03.057","article-title":"Parkinson\u2019s disease: mechanisms, translational models and management strategies","volume":"226","author":"Raza","year":"2019","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.jns.2021.120009_bb0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2021.120009_bb0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"\u03b22-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.120009_bb0125","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1073\/pnas.032654599","article-title":"Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation","volume":"99","author":"Scott","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2021.120009_bb0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jneuroim.2019.03.017","article-title":"Mechanism underlying \u03b22-AR agonist-mediated phenotypic conversion of LPS-activated microglial cells","volume":"332","author":"Sharma","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2021.120009_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fnagi.2017.00176","article-title":"Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s disease","volume":"9","author":"Subramaniam","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jns.2021.120009_bb0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.44.101802.121415","article-title":"DARPP-32: an integrator of neurotransmission","volume":"44","author":"Svenningsson","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.jns.2021.120009_bb0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson\u2019s disease","volume":"13","author":"Ton","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"issue":"11","key":"10.1016\/j.jns.2021.120009_bb0150","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/aje\/kwg068","article-title":"Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity","volume":"157","author":"Van Den Eeden","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.jns.2021.120009_bb0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5414\/CP203559","article-title":"The association between antihypertensive therapy and the incidence of Parkinson's disease in patients followed in general practices in Germany","volume":"57","author":"Warda","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:55:52Z","timestamp":1758383752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":31,"alternative-id":["S0022510X21027052"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120009","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between developing Parkinson's disease and \u03b2-Adrenoceptor acting agents use: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120009"}}